Treating thrombosis in cirrhosis patients with new oral agents: Ready or not?

Publisher： John Wiley & Sons Inc

E-ISSN： 1527-3350|61|2|738-739

ISSN： 0270-9139

Source： HEPATOLOGY, Vol.61, Iss.2, 2015-02, pp. : 738-739

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Increased risk of portal vein thrombosis in patients with cirrhosis due to nonalcoholic steatohepatitis

By  

LIVER TRANSPLANTATION, Vol. 21, Iss. 8, 2015-08 ,pp. : 1016-1021

John Wiley & Sons Inc

Access to resources Recommend Favorite

Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: Results of a longitudinal study

By  

HEPATOLOGY, Vol. 61, Iss. 2, 2015-02 ,pp. : 660-667

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis

By  

HEPATOLOGY RESEARCH, Vol. 45, Iss. 6, 2015-06 ,pp. : 656-662

John Wiley & Sons Inc

Access to resources Recommend Favorite

The use of transjugular intrahepatic portosystemic shunt should be cautious in patients without cirrhosis with obliterative portal vein thrombosis

By  

HEPATOLOGY, Vol. 64, Iss. 4, 2016-10 ,pp. : 1374-1375

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis

By  

HEPATOLOGY RESEARCH, Vol. 48, Iss. 1, 2018-01 ,pp. : 51-58

John Wiley & Sons Inc

Access to resources Recommend Favorite